Correlation Between Biotech Growth and Concurrent Technologies

Can any of the company-specific risk be diversified away by investing in both Biotech Growth and Concurrent Technologies at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biotech Growth and Concurrent Technologies into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between The Biotech Growth and Concurrent Technologies Plc, you can compare the effects of market volatilities on Biotech Growth and Concurrent Technologies and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biotech Growth with a short position of Concurrent Technologies. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biotech Growth and Concurrent Technologies.

Diversification Opportunities for Biotech Growth and Concurrent Technologies

0.1

Correlation Coefficient

Biotech Growth  Concurrent Technologies

Average diversification

The 3 months correlation between Biotech and Concurrent is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding The Biotech Growth and Concurrent Technologies Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Concurrent Technologies and Biotech Growth is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on The Biotech Growth are associated (or correlated) with Concurrent Technologies. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Concurrent Technologies has no effect on the direction of Biotech Growth i.e., Biotech Growth and Concurrent Technologies go up and down completely randomly.

Pair Corralation between Biotech Growth and Concurrent Technologies

Assuming the 90 days trading horizon Biotech Growth is expected to generate 1.39 times less return on investment than Concurrent Technologies. But when comparing it to its historical volatility, The Biotech Growth is 1.34 times less risky than Concurrent Technologies. It trades about 0.09 of its potential returns per unit of risk. Concurrent Technologies Plc is currently generating about 0.09 of returns per unit of risk over similar time horizon. If you would invest  16,134  in Concurrent Technologies Plc on April 24, 2025 and sell it today you would earn a total of  1,916  from holding Concurrent Technologies Plc or generate 11.88% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

The Biotech Growth  vs.  Concurrent Technologies Plc

Biotech Growth

Risk-Adjusted Performance

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in The Biotech Growth are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Biotech Growth may actually be approaching a critical reversion point that can send shares even higher in August 2025.

Concurrent Technologies

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Concurrent Technologies Plc are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain technical and fundamental indicators, Concurrent Technologies exhibited solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Biotech Growth and Concurrent Technologies

The main advantage of trading using opposite Biotech Growth and Concurrent Technologies positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biotech Growth position performs unexpectedly, Concurrent Technologies can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Concurrent Technologies will offset losses from the drop in Concurrent Technologies' long position.

The idea behind The Biotech Growth and Concurrent Technologies Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.